Recommanded Product: 620-20-2On May 13, 2021 ,《Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase》 appeared in Journal of Medicinal Chemistry. The author of the article were Stanford, Stephanie M.; Diaz, Michael A.; Ardecky, Robert J.; Zou, Jiwen; Roosild, Tarmo; Holmes, Zachary J.; Nguyen, Tiffany P.; Hedrick, Michael P.; Rodiles, Socorro; Guan, April; Grotegut, Stefan; Santelli, Eugenio; Chung, Thomas D. Y.; Jackson, Michael R.; Bottini, Nunzio; Pinkerton, Anthony B.. The article conveys some information:
Obesity-associated insulin resistance plays a central role in the pathogenesis of type 2 diabetes. A promising approach to decrease insulin resistance in obesity is to inhibit the protein tyrosine phosphatases that neg. regulate insulin receptor signaling. The low-mol.-weight protein tyrosine phosphatase (LMPTP) acts as a critical promoter of insulin resistance in obesity by inhibiting phosphorylation of the liver insulin receptor activation motif. Here, we report development of a novel purine-based chem. series of LMPTP inhibitors. These compounds inhibit LMPTP with an uncompetitive mechanism and are highly selective for LMPTP over other protein tyrosine phosphatases. We also report the generation of a highly orally bioavailable purine-based analog that reverses obesity-induced diabetes in mice. The experimental part of the paper was very detailed, including the reaction process of 3-Chlorobenzylchloride(cas: 620-20-2Recommanded Product: 620-20-2)
3-Chlorobenzylchloride(cas: 620-20-2) has been used in the reaction of 3-methoxybenzyl chloride and ethyl 4-bromobenzoate in pure water, using zinc dust and a Pd catalyst.Recommanded Product: 620-20-2
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics